<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02151487</url>
  </required_header>
  <id_info>
    <org_study_id>102013-068</org_study_id>
    <nct_id>NCT02151487</nct_id>
  </id_info>
  <brief_title>A Comparison of Ropivacaine Alone Versus Combination of Dexamethasone and Clonidine for Block</brief_title>
  <official_title>A Comparison of Ropivacaine Alone Versus Ropivacaine With Dexamethasone or Clonidine Versus a Combination of Ropivacaine, Dexamethasone, and Clonidine for Supraclavicular Brachial Plexus Block Using Ultrasound:A Prospective, Observer-blinded, Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomized, observer-blinded study is to evaluate the postoperative analgesic
      efficacy of adding dexamethasone and clonidine to ropivacaine in supraclavicular nerve block.
      The investigators hypothesized that addition of dexamethasone and clonidine to ropivacaine
      would prolong the duration of analgesia in supraclavicular nerve block compared with
      ropivacaine alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects undergoing orthopedic surgery of upper extremities were randomized to be one of the
      three groups to receive supraclavicular nerve block with group 1: ropivacaine alone; group 2:
      ropivacaine and dexamethasone; group 3: ropivacaine and clonidine or group 4: ropivacaine and
      dexamethasone and clonidine combination.

      Subjects were identified at the day surgery unit at Parkland hospital before the procedure
      and approached by their physician, the primary investigator, or research personnel for the
      consent for the study. If the subjects chooses and consents fully to participate, he or she
      was randomly assigned to receive one of the previously described local anesthetics for
      supraclavicular nerve block.

      The following clinical outcomes were assessed for up to 24 hr: Duration of the block, onset
      of the block, postoperative pain scores, nausea, vomiting, and complications of peripheral
      nerve block. Pain was evaluated by using a linear 10-cm visual analog scale (VAS; 0=no pain,
      10= worst imaginable pain) immediately before the block, 5, 10, 15 minutes and
      postoperatively on the arrival of Post Anesthesia Care Unit (PACU) within 15 minutes,
      discharge from the Day surgery Unit, and 24 hr. later at home via phone call visit.

      Sensory and motor block in the related nerve dermatomes were assessed. Patient was instructed
      to document at what time did hand motion (finger movement) return and what time normal
      sensation return. Specific time for both events was sked to patient at phone call visit 24 hr
      later. Overall patient satisfaction was evaluated at the discharge from the day surgery and
      24 hr after the block via phone visit.

      At any point in which the patient is not experiencing pain relief after having received the
      injection, they were removed from the study and other anesthetic techniques will be applied
      to resolve their pain along with pharmacological management of their pain. Rescue antiemetic,
      which is standard of care, will be given to any patient who complains of nausea or vomiting.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 2014</start_date>
  <completion_date type="Actual">August 20, 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of the Sensorial Supraclavicular Block</measure>
    <time_frame>within 24-hr after surgery</time_frame>
    <description>Duration of sensorial block defined as the time interval between subject admitted to the Post-Anesthesia Care Unit and the time the first pain medication taken at home</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Postoperative Analgesia</measure>
    <time_frame>within 15 minutes at postanesthesia care unit (PACU) arrival</time_frame>
    <description>Post-operative Visual Analog Pain (VAS) scores on the scale of 10 (0=no pain and 10=worse imaginary pain).</description>
  </secondary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">97</enrollment>
  <condition>Upper Extremity Surgery</condition>
  <arm_group>
    <arm_group_label>Ropivacaine</arm_group_label>
    <description>Ropivacaine 0.5% 25 ml alone for supraclavicular block</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine and dexamethasone</arm_group_label>
    <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine and clonidine</arm_group_label>
    <description>25 ml 0.5% ropivacaine + 100 mcg clonidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ropivacaine, dexamethasone and clonidine</arm_group_label>
    <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine</intervention_name>
    <description>Ropivacaine alone</description>
    <arm_group_label>Ropivacaine</arm_group_label>
    <other_name>Noropin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine and dexamethasone</intervention_name>
    <description>Ropivacaine combination with dexamethasone</description>
    <arm_group_label>Ropivacaine and dexamethasone</arm_group_label>
    <other_name>Noropin and adjuvant</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine and clonidine</intervention_name>
    <description>Ropivacaine combination with clonidine</description>
    <arm_group_label>Ropivacaine and clonidine</arm_group_label>
    <other_name>Noropin and adjuvants</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ropivacaine, dexamethasone and clonidine</intervention_name>
    <description>Ropivacaine combination with dexamethasone and clonidine</description>
    <arm_group_label>Ropivacaine, dexamethasone and clonidine</arm_group_label>
    <other_name>Noropin and adjuvants</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who scheduled to undergo upper extremity surgery requiring USSB for postoperative
        analgesia with ropivacaine alone or ropivacaine and adjuvants.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men and women 18-80 years old

          -  Undergoing upper extremity surgery

          -  Receiving Supraclavicular block

          -  Receiving ropivacaine, ropivacaine adjuvants (dexamethasone, clonidine) for the
             supraclavicular nerve block.

          -  Able to give Informed consent

        Exclusion Criteria:

          -  Age less than 18 and greater than 80 years

          -  Inability to understand the study procedures

          -  Significant respiratory dysfunction

          -  Preexisting neurologic deficits

          -  Allergy to local anesthetics

          -  A bleeding diathesis or on anticoagulants

          -  Systemic glucocorticoid use

          -  Refuse to participate in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dawood Nasir, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Texas Southwestern Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Parkland Health Hospital System</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>750390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>May 29, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 30, 2014</study_first_posted>
  <results_first_submitted>April 20, 2018</results_first_submitted>
  <results_first_submitted_qc>April 15, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 5, 2019</results_first_posted>
  <last_update_submitted>April 15, 2019</last_update_submitted>
  <last_update_submitted_qc>April 15, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Texas Southwestern Medical Center</investigator_affiliation>
    <investigator_full_name>Dawood Nasir</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Supraclavicular block</keyword>
  <keyword>Ropivacaine</keyword>
  <keyword>Dexamethasone</keyword>
  <keyword>Clonidine</keyword>
  <keyword>Postoperative analgesia</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Clonidine</mesh_term>
    <mesh_term>Ropivacaine</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Study takes place in routine clinical context. Subjects who received supraclavicular nerve block with ropivacaine alone or ropivacaine with adjuvants enrolled to the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ropivacaine</title>
          <description>Ropivacaine 0.5% 25 ml alone for supraclavicular block
Ropivacaine: Ropivacaine alone</description>
        </group>
        <group group_id="P2">
          <title>Ropivacaine and Dexamethasone</title>
          <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone
Ropivacaine and dexamethasone: Ropivacaine combination with dexamethasone</description>
        </group>
        <group group_id="P3">
          <title>Ropivacaine and Clonidine</title>
          <description>25 ml 0.5% ropivacaine + 100 mcg clonidine
Ropivacaine and clonidine: Ropivacaine combination with clonidine</description>
        </group>
        <group group_id="P4">
          <title>Ropivacaine, Dexamethasone and Clonidine</title>
          <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine
Ropivacaine, dexamethasone and clonidine: Ropivacaine combination with dexamethasone and clonidine</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="20"/>
                <participants group_id="P4" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ropivacaine</title>
          <description>Ropivacaine 0.5% 25 ml alone for supraclavicular block
Ropivacaine: Ropivacaine alone</description>
        </group>
        <group group_id="B2">
          <title>Ropivacaine and Dexamethasone</title>
          <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone
Ropivacaine and dexamethasone: Ropivacaine combination with dexamethasone</description>
        </group>
        <group group_id="B3">
          <title>Ropivacaine and Clonidine</title>
          <description>25 ml 0.5% ropivacaine + 100 mcg clonidine
Ropivacaine and clonidine: Ropivacaine combination with clonidine</description>
        </group>
        <group group_id="B4">
          <title>Ropivacaine, Dexamethasone and Clonidine</title>
          <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine
Ropivacaine, dexamethasone and clonidine: Ropivacaine combination with dexamethasone and clonidine</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="27"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="20"/>
            <count group_id="B4" value="23"/>
            <count group_id="B5" value="97"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Participants were ambulatory cases and followed with 24 h phone call visit. Due to follow-up lost, analysis population is lower than overall population.</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="16"/>
                    <count group_id="B4" value="20"/>
                    <count group_id="B5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49" spread="16"/>
                    <measurement group_id="B2" value="43" spread="14"/>
                    <measurement group_id="B3" value="48" spread="11"/>
                    <measurement group_id="B4" value="50" spread="11"/>
                    <measurement group_id="B5" value="48" spread="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Subjects were ambulatory surgery cases and followed via phone call visit 24 hours after discharge.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="25"/>
                    <count group_id="B2" value="22"/>
                    <count group_id="B3" value="16"/>
                    <count group_id="B4" value="20"/>
                    <count group_id="B5" value="83"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Duration of the Sensorial Supraclavicular Block</title>
        <description>Duration of sensorial block defined as the time interval between subject admitted to the Post-Anesthesia Care Unit and the time the first pain medication taken at home</description>
        <time_frame>within 24-hr after surgery</time_frame>
        <population>Participants received supraclavicular nerve block with ropivacaine alone and ropivacaine with adjuvants.</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine</title>
            <description>Ropivacaine 0.5% 25 ml alone for supraclavicular block
Ropivacaine: Ropivacaine alone</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine and Dexamethasone</title>
            <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone
Ropivacaine and dexamethasone: Ropivacaine combination with dexamethasone</description>
          </group>
          <group group_id="O3">
            <title>Ropivacaine and Clonidine</title>
            <description>25 ml 0.5% ropivacaine + 100 mcg clonidine
Ropivacaine and clonidine: Ropivacaine combination with clonidine</description>
          </group>
          <group group_id="O4">
            <title>Ropivacaine, Dexamethasone and Clonidine</title>
            <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine
Ropivacaine, dexamethasone and clonidine: Ropivacaine combination with dexamethasone and clonidine</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of the Sensorial Supraclavicular Block</title>
          <description>Duration of sensorial block defined as the time interval between subject admitted to the Post-Anesthesia Care Unit and the time the first pain medication taken at home</description>
          <population>Participants received supraclavicular nerve block with ropivacaine alone and ropivacaine with adjuvants.</population>
          <units>hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.4" spread="6"/>
                    <measurement group_id="O2" value="14" spread="6.6"/>
                    <measurement group_id="O3" value="17.4" spread="6"/>
                    <measurement group_id="O4" value="18.8" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Postoperative Analgesia</title>
        <description>Post-operative Visual Analog Pain (VAS) scores on the scale of 10 (0=no pain and 10=worse imaginary pain).</description>
        <time_frame>within 15 minutes at postanesthesia care unit (PACU) arrival</time_frame>
        <population>Patients received supraclavicular nerve block with ropivacaine alone or ropivacaine with adjuvants. Postoperative pain was evaluated by using Visual Analog Pain Scores on the scale of 10 (0=no pain and 10-worse pain).</population>
        <group_list>
          <group group_id="O1">
            <title>Ropivacaine</title>
            <description>Ropivacaine 0.5% 25 ml alone for supraclavicular block
Ropivacaine: Ropivacaine alone</description>
          </group>
          <group group_id="O2">
            <title>Ropivacaine and Dexamethasone</title>
            <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone
Ropivacaine and dexamethasone: Ropivacaine combination with dexamethasone</description>
          </group>
          <group group_id="O3">
            <title>Ropivacaine and Clonidine</title>
            <description>25 ml 0.5% ropivacaine + 100 mcg clonidine
Ropivacaine and clonidine: Ropivacaine combination with clonidine</description>
          </group>
          <group group_id="O4">
            <title>Ropivacaine, Dexamethasone and Clonidine</title>
            <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine
Ropivacaine, dexamethasone and clonidine: Ropivacaine combination with dexamethasone and clonidine</description>
          </group>
        </group_list>
        <measure>
          <title>Postoperative Analgesia</title>
          <description>Post-operative Visual Analog Pain (VAS) scores on the scale of 10 (0=no pain and 10=worse imaginary pain).</description>
          <population>Patients received supraclavicular nerve block with ropivacaine alone or ropivacaine with adjuvants. Postoperative pain was evaluated by using Visual Analog Pain Scores on the scale of 10 (0=no pain and 10-worse pain).</population>
          <units>score on a scale of 10</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="16"/>
                <count group_id="O4" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O3" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O4" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Following nerve block to postoperative 24 hour period.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ropivacaine</title>
          <description>Ropivacaine 0.5% 25 ml alone for supraclavicular block
Ropivacaine: Ropivacaine alone</description>
        </group>
        <group group_id="E2">
          <title>Ropivacaine and Dexamethasone</title>
          <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone
Ropivacaine and dexamethasone: Ropivacaine combination with dexamethasone</description>
        </group>
        <group group_id="E3">
          <title>Ropivacaine and Clonidine</title>
          <description>25 ml 0.5% ropivacaine + 100 mcg clonidine
Ropivacaine and clonidine: Ropivacaine combination with clonidine</description>
        </group>
        <group group_id="E4">
          <title>Ropivacaine, Dexamethasone and Clonidine</title>
          <description>25 ml 0.5% ropivacaine + 4 mg dexamethasone + 100 mcg clonidine
Ropivacaine, dexamethasone and clonidine: Ropivacaine combination with dexamethasone and clonidine</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Shorness of breath</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Shortness of breath (SOB)</sub_title>
                <description>Shortness of breath immediately after nerve block</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dawood Nasir</name_or_title>
      <organization>UT Southwestern Medical Center</organization>
      <phone>214-590-5352</phone>
      <email>Dawood.Nasir@UTSouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

